We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Alfimeprase for Thrombolysis in Acute Peripheral Arterial Occlusion

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00073554
First Posted: November 26, 2003
Last Update Posted: December 17, 2009
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Health Decisions
Information provided by:
ARCA Biopharma, Inc.
  Purpose
This trial is for patients with acute occlusion of one of the arteries supplying blood to the leg. The trial is designed to determine the safety and activity of a novel clot dissolving (thrombolytic) drug (alfimeprase).

Condition Intervention Phase
Arterial Occlusive Diseases Peripheral Vascular Diseases Thrombosis Drug: Alfimeprase Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety and Activity of Alfimeprase in Patients With Acute Peripheral Arterial Occlusion

Further study details as provided by ARCA Biopharma, Inc.:

Estimated Enrollment: 100
Study Start Date: June 2003
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
  • Patients with acute peripheral arterial occlusion of the lower limb (onset of symptoms within 14 days)
  • Rutherford Class I or IIa (minimal sensory loss, no muscle weakness, audible venous flow)
  • Age 18 or above
  • Able to consent
  • Able to follow up
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00073554


Locations
United States, Ohio
Cleveland Clinic Foundation
Cleveland, Ohio, United States
Sponsors and Collaborators
ARCA Biopharma, Inc.
Health Decisions
  More Information

Publications:
ClinicalTrials.gov Identifier: NCT00073554     History of Changes
Other Study ID Numbers: HA002
NAPA-1
First Submitted: November 24, 2003
First Posted: November 26, 2003
Last Update Posted: December 17, 2009
Last Verified: November 2006

Additional relevant MeSH terms:
Thrombosis
Vascular Diseases
Peripheral Vascular Diseases
Peripheral Arterial Disease
Arterial Occlusive Diseases
Embolism and Thrombosis
Cardiovascular Diseases
Atherosclerosis
Arteriosclerosis


To Top